

***Recurrent Hepatitis C Virus Infection
In Egyptian Patients Post-Liver Transplantation***

Thesis

**Submitted for Partial Fulfillment of
Master Degree in Tropical Medicine**

By

Eman Mohamed Hasaneen

M.B.B.CH.

Supervised by

Professor Doctor/ Eman Mohamed El-Gindy

*Professor of Tropical Medicine
Faculty of Medicine -Ain Shams University*

General Doctor/ Medhat Hassan El-Sahhar

*M.D. Tropical Medicine
Police Hospital, Agouza*

Doctor/ Runia Fouad El-Folly

*Assisstant Professor of Tropical Medicine
Faculty of Medicine- Ain Shams University*

***Faculty of Medicine
Ain Shams University
2015***



بسم الله الرحمن الرحيم

قالوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا

عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

سورة البقرة آية (٣٢)

ACKNOWLEDGEMENT

First and foremost thanks to ALLAH, the most merciful.

I wish to express my deepest appreciation and sincere gratitude to **Prof. Dr. Eman Mohamed El-Gindy**, Professor of Tropical Medicine, Faculty of Medicine, Ain Shams University, for her continuous encouragement, kind supervision and valuable instructions. It was a great honor to me to work under her supervision.

Words can never express my deepest gratitude, appreciation and greatest respect to **General Dr. Medhat Hassan El Sahhar**, General Manager of Police Hospital- Agouza for his great help and advice.

I am also delighted to express my deep gratitude and thanks to **Dr. Runia Fouad EL-Folly**, Assistant Professor of Tropical Medicine, Faculty of Medicine, Ain Shams University, for her close supervision, continuous guidance, great help and indispensable advice in every step of this work.

Especial thanks to my husband for his support and standing with me during my work. **Last** but not least, I would like to thank my mother, her support and encouragement. I would also like to dedicate this achievement to the soul of my father and thank him for his unconditional support, both financially and emotionally throughout my degree.

Eman M. Hasaneen

2015

List of contents

<i>Subject</i>	<i>Page</i>
<ul style="list-style-type: none"> • List of Tables • List of Figures • List of Abbreviations 	<div style="text-align: center;"> I IV V </div>
<i>Protocol</i>	--
<i>Introduction</i>	1
<i>Aim of work</i>	4
<i>Review of literature</i> <ul style="list-style-type: none"> • Chapter I: Hepatitis C Virus • Chapter II: Liver transplantation • Chapter III: Recurrence of HCV Post Liver transplantation 	<div style="text-align: center;"> 5 39 76 </div>
<i>Patients and Methods</i>	91
<i>Results</i>	112
<i>Discussion</i>	137
<i>Summary</i>	153
<i>Conclusions</i>	159
<i>Recommendation</i>	160
<i>References</i>	161
<i>Arabic summary</i>	--

List of tables

<i>Table</i>	<i>Subject</i>	<i>Page</i>
<u>Tables of Review</u>		
Table (I):	Persons for whom HCV testing is recommended.	9
Table (II):	Ishak system (Ishak scoring system)	18
Table (III):	Metavir scoring system	20
<u>Tables of Results</u>		
Table (1):	Preoperative characteristics of the studied cases and the donors.	114
Table (2):	Operative and Post-operative events among the transplanted studied cases.	115
Table (3):	Laboratory data before and after transplantation.	116
Table (3a):	ALT serum level before and after LT.	116
Table (3b):	AST before and after LT.	117
Table (4):	Child Classification before and after LT.	118
Table(5):	Pathological finding of liver biopsy	118
Table (5a):	Biopsy grading after LT.	120
Table (5b):	Biopsy staging after LT.	120
Table (6):	Quantitative HCV RNA before and after LT.	121
Table (7):	Positive HCV RNA before and after LT.	122

Table (8):	Recurrence of HCV RNA Viremia after LT.	123
Table (9):	Recurrence of HCV disease after LT.	124
Table (10):	Percent of Recurrence of HCV disease after LT.	126
Table (11):	Comparison between recurrent and non-recurrent HCV disease regarding the outcome of the combined ttt. of HCV disease.	128
Table (12):	Comparison between post-LT treated and non-treated recurrent cases at 1- year post LT.	130
Table (13):	Comparison between the recurrent and non-recurrent HCV disease regarding pre-operative characteristics	131
Table (14):	Comparison between the recurrent and non-recurrent HCV disease regarding operative and post-operative parameters.	132
Table (15):	Comparison between recurrent and non-recurrent HCV disease before LT.	133
Table (16):	Comparison between recurrent and non-recurrent HCV disease at 3-months follow up post LT.	134
Table (17):	Comparison between recurrent and non-recurrent HCV disease at 2 years follow up post LT.	135
Table(18) :	Comparison between recurrent and non-recurrent HCV disease at 3 years follow up post LT.	136

List of figures

<i>Figure</i>	<i>Subject</i>	<i>Page</i>
	<u>Figures of Review</u>	
Figure (I):	Global prevalence of hepatitis C.	7
Figure (II):	Global distribution of Hepatitis C virus genotypes.	8
Figure (III):	Natural history of HCV.	10
Figure (IV):	Interferon action in the body.	22
<u>Figures of Results</u>		
Figure (1a):	Median ALT before and after LT.	116
Figure (1b):	Median AST before and after LT.	117
Figure (2):	Child classification before and after LT.	118
Figure (3a):	Mean biopsy grading after LT.	119
Figure (3b):	Mean biopsy staging after LT.	120
Figure (4):	Median HCV RNA before and after LT.	121
Figure (5):	Positive HCV RNA before and after LT.	122
Figure (6):	Recurrence HCV RNA Viremia after LT.	123
Figure (7):	Recurrence HCV RNA disease after LT.	124
Figure (8):	Percent of Recurrence of liver disease after LT.	126

List of abbreviations

AZA	Azathioprine.
ADV	Adefovir dipivoxil.
AIH	Autoimmune Hepatitis.
ALT	Alanine aminotransferase.
APRI	AST to Platelets Ratio Index.
ARF	Acute renal failure.
AST	Aspartate aminotransferase.
AVH	Acute viral hepatitis.
CBC	Complete blood count.
CDC	Centers for Disease Control and Prevention.
CHC	Chronic Hepatitis C.
CLD	Chronic liver disease.
CMV	Cytomegalovirus.
CNIs	Calcineurin inhibitors.
CNS	Central nervous system.
CPM	Central Pontine myelinolysis.
CsA	Cyclosporine.

DAA s	Direct antiviral agents.
DDLT	Deceased donor liver transplantation
DNA	Deoxyribonucleic acid.
EBV	Epstein Barr Virus.
EIA	Enzyme immunoassay.
ESLD	End stage liver disease.
EPO	Erythropoietin.
ETV	Entecavir.
EVR	Early virologic response.
GTP	Guanosine triphosphate.
HBV	Hepatitis B virus.
HCC	Hepatocellular carcinoma.
HE	Hepatic Encephalopathy.
HIV	Human immunodeficiency virus.
HPV	Human Papilloma Virus.
HRS	Hepatic renal syndrome.
IFN-a	Interferon a.
IMPDH	Inosine monophosphate dehydrogenase.

INR	International normalized ratio.
LAM	Long term Lamivudine.
LT	Liver Transplantation.
MELD	Model of end stage liver disease.
MMF	Mycophenolate mofetil.
MPA	Mycophenlic acid.
OLT	Orthotopic liver transplantation.
PAT	Parenteral Antischistosomal therapy.
PBC	Primary Biliary Cirrhosis.
PCR	Polymerase chain reaction.
PEG-IFN	Pegylated interferon.
PIs	Polymerase inhibitors
PSC	Primary sclerosing cholangitis.
PTLD	Post transplant lymphoproliferative disease.
RMP	Ribavirin-5- monophosphate.
RNA	Ribonucleic acid.
RTP	Ribavirin-5-triphosphate.
RT-PCR	Real-Time polymerase chain reaction.

SVR	Sustained virologic response.
TAC	Tacrolimus.
TDF	Tenofovir.
TIPS	Transjugular intrahepatic portosystemic shunts.
WHO	World Health Organization.

**Recurrent Hepatitis C Virus Infection
In Egyptian Patients Post-Liver Transplantation**

Thesis

**Submitted for Partial Fulfillment of
Master Degree in Tropical Medicine**

By

Eman Mohammed Hasaneen
M.B.B.CH. Ain Shams University

Supervised by

Professor Doctor/ Eman Mohamed El-Gindy
Professor of Tropical Medicine
Faculty of Medicine
Ain Shams University

General Doctor/ Medhat Hassan El-Sahhar
M.D. Tropical Medicine
Police Hospital, Agouza

Doctor/ Runia Fouad El-Folly
Lecturer of Tropical Medicine
Faculty of Medicine
Ain Shams University

**Faculty of Medicine
Ain Shams University
2010**

Recurrent hepatitis C virus Infection In Egyptian Patients Post Liver Transplantation

INTRODUCTION:

Hepatitis C virus (HCV) has been estimated by the World Health Organization (WHO) to infect 170 million patients worldwide, with the highest prevalence rate among Egyptians (14% - 18%; approximately 10-fold greater than in the United States and Europe) (*Mohamed et al., 2005*). Because of the very high prevalence rate of HCV in the general Egyptian population, it accounts for most chronic liver disease and HCC cases in Egypt (*Hassan et al., 2001*; *Strickland et al., 2002*).

Hepatitis C virus genotype 4 (HCV-4) is the most common variant of the hepatitis C virus (HCV) in the Middle East and Africa, particularly Egypt. This region has the highest prevalence of HCV worldwide, with more than 90% of infections due to genotype 4 (*Kamal et al., 2008*).

HCV is the most frequent indication for *liver transplantation (LT)* in the United States and in Europe. With the anticipated increase in patients requiring LT for HCV related liver disease, development of effective strategies to

reduce graft failure due to HCV recurrence is essential (*Schiano and Martin, 2006*). Recurrence of HCV following *living donor liver transplantation (LDLT)* occurs in over 95 percent of patients (*Dickson et al., 1996*)

Previous studies looking at large numbers of patients with adequate long-term follow-up have confirmed that patients with HCV undergoing liver transplantation have increased morbidity and mortality and have lower 5 and 10 year survival rates when compared to patients undergoing liver transplantation for other etiologies of cirrhosis (*Brown, 2005*).

However, recurrent hepatitis C virus infection will remain the most frequent form of recurrent disease in liver transplant programs in future (*Schiano and Martin, 2006*). HCV recurrence following LDLT in HCV-genotype 4 patients is not significantly different from its recurrence for other genotypes (*Mudawi et al., 2009*).

Post-transplant antiviral therapy in those with evidence of recurrent disease is the mainstay of management. A combination of pegylated interferon and ribavirin is the treatment of choice, and sustained virologic response is achieved with 48 weeks of treatment in approximately 30% of treated patients. Attainment of early loss of hepatitis C virus

RNA is highly predictive of sustained virologic response. Histologic improvements are seen in responders. Survival is prolonged among those achieving a sustained virologic response (*Terrault, 2008*)

Risk factors for severe recurrent HCV include advanced donor age, HCV genotype 1, high HCV RNA levels before and after transplant, early histological recurrence of HCV, concomitant cytomegalovirus infection, the use of T lymphocyte-depleting immunosuppressive agents such as OKT3, and treatment of presumed acute cellular rejection with pulse corticosteroids. Data are conflicting as to whether recipient age, warm or cold ischemia times, gender, HLA mismatch, ethnicity or pre-transplant severity of illness influence the rate of recurrent HCV and its severity (*Brown, 2005*).

A number of reports have described accelerated fibrosis progression post-liver transplantation and this may in part be due to the age of the donor liver allograft (*Berenguer et al., 2002*).

Also, postoperative patient and graft survival rates for HCV (genotype 4)-related cirrhosis are more or less comparable to *deceased-donor liver transplants (DDLT)* reported in the literature. Clinical HCV recurrence after *living*
